



ISSN: 1741-5993 (Print) 1741-6000 (Online) Journal homepage: https://www.tandfonline.com/loi/gsrp20

Synthesis and antimicrobial activity of new thiazole and thiadiazole derivatives via ethyl pyruvate

Fatma M. Saleh, Abdou O. Abdelhamid & Hamdi M. Hassaneen

To cite this article: Fatma M. Saleh, Abdou O. Abdelhamid & Hamdi M. Hassaneen (2019): Synthesis and antimicrobial activity of new thiazole and thiadiazole derivatives via ethyl pyruvate, Journal of Sulfur Chemistry, DOI: 10.1080/17415993.2019.1694678

To link to this article: https://doi.org/10.1080/17415993.2019.1694678



Published online: 01 Dec 2019.



🖉 Submit your article to this journal 🗗





View related articles



🌔 🛛 View Crossmark data 🗹



Check for updates

Synthesis and antimicrobial activity of new thiazole and thiadiazole derivatives *via* ethyl pyruvate

Fatma M. Saleh 💿 , Abdou O. Abdelhamid 💿 and Hamdi M. Hassaneen 💿

Faculty of Science, Department of Chemistry, Cairo University, Giza, Egypt

ABSTRACT

Reaction of ethyl 2-(2-((methylthio)carbonothioyl)hydrazono)pro panoate (2) and ethyl 2-(2-carbamothioyl-hydrazono)propanoate (3) with hydrazonoyl halides **4a-e** afforded the corresponding thiadiazoles **5a-e**. Also, treatment of compound 2 with α -ketohydrazonoyl halides **12a-f** in absolute ethanol and in the presence of triethylamine gave the corresponding thiadiazoles **13a-f**; while reaction of ethyl 2-(2-carbamothioyl-hydrazono)propanoate (3) with α ketohydrazonoyl halide **12** gave thiazole derivatives **15**. Also, the reaction of compound **3** with hydrazonoyl chloride **12f** afforded thiazolone derivative **18**. Antimicrobial studies are performed using two-gram positive bacteria and two-gram negative bacteria. Data revealed that thiazole derivative **17a** achieved the lowest MIC values (high efficient derivative) against the sensitive bacterial strain *S. aureus* with MIC value 160 µg/ml.



ARTICLE HISTORY

Received 26 September 2019 Accepted 9 November 2019

KEYWORDS

Ethyl pyruvate; thiosemicarbazide; methyl hydrazinecarbodithioate; hydrazonoyl halides; thiadiazoles; thiazoles

Introduction

Ethyl pyruvate is a simple ester of pyruvate and stable lipophilic ester obtained from the endogenous metabolite pyruvate and has been exhibited to protect against inflammation [1] and to mitigate organ dysfunction in several animal models of diverse disorders, including severe sepsis, burns and acute pancreatitis [2,3]. Also, ethyl pyruvate has been revealed

© 2019 Informa UK Limited, trading as Taylor & Francis Group

2 😔 F. M. SALEH ET AL.

to possess a protective effect on acute lung injury (ALI), probably through the inhibition of the mitogen-activated protein kinase (MAPK) pathway in lungs [4–6]. Ethyl pyruvate is an important intermediate of organic synthesis with wide applications inhibits the growth of cells relying predominantly on glycolysis [7], antitumor [8], antitrypanosome activity [9], and other industrial and pharmaceutical applications [2,10–14]. The oxazolone synthesized from ethyl pyruvate widely used for the synthetic fungicides [15,16]. It is well known that thiadiazole derivatives are formed *via* reaction of hydrazonoyl halides with potassium thiocyanate [17–21] or by coupling of 1-substitutedl-2-thiocyanatoethan-1-one with *arenediazonium chlorides* [22,23]. Also, thiazole derivatives were prepared *via* reaction of thiourea with α -ketohydrazonoyl halide [24] or with phenacyl bromide [24]. We report herein the utility of ethyl pyruvate in the synthesis of new thiadiazole and thiazole having many functional groups and study the biological activities of some new synthesized compounds.

Results and discussion

Refluxing of ethyl pyruvate (1A) with methyl hydrazinecarbodithioate in 2-propanol afforded ethyl 2-(2-((methylthio)carbonothioyl)hydrazono)propanoate (2) [25–27] (Scheme 1). Stirring of compound 2 with the appropriate hydrazonoyl halides 4a-e in absolute ethanol in the presence of triethylamine at room temperature afforded the corresponding thiadiazoles 5a-e, respectively (Scheme 2). The structures of isolated products 5a-e were established by their spectral data and elemental analyses.

Also, treatment of ethyl 2-(2-carbamothioylhydrazono)propanoate (3) [28] with hydrazonoyl halides **4a–e** in refluxing ethanol in the presence of triethylamine gave, in each case, one isolated product which proved identical in all respects (mp, mixed mp, IR, ¹H NMR, ¹³C NMR and MS spectra) with the corresponding derivatives **5** (Scheme 2). Moreover, the structures of **5a–e** were confirmed by alternative synthesis. For example, thiadiazole **5a** was obtained *via* refluxing 2-hydrazono-1,3,4-thiadiazole derivative **6a** (prepared from



Scheme 1. Synthesis of ethyl 2-(2-((methylthio)carbonothioyl)hydrazono)propanoate (**2**) and ethyl 2-(2-carbamothioyl-hydrazono)propanoate (**3**).

JOURNAL OF SULFUR CHEMISTRY 🕒 3



4,5,6: R (Ar): a , C_6H_5 (C_6H_5); b, $C_6H_5CH=CH$ (C_6H_5); c, $2\text{-}C_4H_3O$ (4-NO $_2C_6H_4$); d, $2\text{-}C_4H_3S$ (4-NO $_2C_6H_4$); e, $C_6H_5NHCO(C_6H_5)$





Scheme 3. A plausible mechanism for the formation 1,3,4-thiadiazole derivatives 5.

reaction of methyl hydrazinecarbodithioate (**2**) with hydrazonoyl halides **4a** [29–32]) with ethyl pyruvate in 2-propanol.

In light of these results, the mechanism outlined in Scheme 3 seems to be the most plausible pathway for the formation of **5a–e** from the reaction of the **3** or **2** with **4**. The reaction involves the initial formation of thiohydrazonates **8**, **10** *via* 1,3-addition, which undergoes intramolecular cyclization as soon as it is formed to yield the intermediate **9**, **11** or *via* 1,3-dipolar cycloaddition of nitrilimines **7** to CS double bond of **3** or **2**, which afforded intermediate **9** or **11** which gave a final product **5** by elimination of ammonia or methyl mercaptan, respectively [33,34].



12, 13 R: a, C₆H₅; b, 2-C₁₀H₇; c, CH₃; d, 2-C₄H₃S; e, 2-C₄H₃O; f, OC₂H₅

Scheme 4. Synthesis of 1,3,4-thiadiazoles 13a-f.

Analogously, treatment of α -ketohydrazonoyl halides **12a–f** with compound **2** in ethanolic triethylamine yielded 1,3,4-thiadiazoles **13a–f** in a good yield (Scheme 4). Structures of **13a–f** were confirmed based on elemental analysis, spectral data and alternative synthetic route. For example, treatment of ethyl 5-hydrazono-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (**14**) [32] with **1A** in 2-propanol gave product identical in all respect mp, mixed mp, and spectra with compound **13f**.

In contrast, treatment of α -ketohydrazonoyl halide 12a with compound 3 in boiling ethanol and in the presence of triethylamine gave one isolable product in each case, and the products formulated as: ethyl 2-(2-(4-substituted-5-(phenyldiazenyl)-thiazol-2yl)hydrazono)propanoate (15a) (Scheme 5). Structures 15 were elucidated on the base of elemental analyses, spectral data and alternative synthetic route. Thus, reaction of ethyl 2-(2-carbamothioylhydrazono)propanoate (3) with ω -bromoacetophenone (16a) in boiling ethanol gave the corresponding thiazoles 17a. Coupling of the latter compound 17a with benzenediazonium chloride in ethanolic sodium acetate solution gave a product identical in all respect (mp, mixd mp and spectra) with 15a (Scheme 5). Its mass spectrum showed an intense peak, base peak, at m/z = 393 which corresponding to its molecular weight. The IR spectrum showed two characteristic bands at v 3429 and 1697 cm^{-1} assignable to NH and C = O stretching frequencies, respectively. Also, the ¹H NMR spectrum revealed signals at δ 1.31 ppm (t, J = 7 Hz, 3H) and 4.27 ppm (q, J = 7 Hz, 2H) corresponding to ethoxycarbonyl group, singlet signal at 2.14 ppm (CH₃) and a singlet signal at δ 11.38 ppm exchangeable with deuterium oxide assignable to NH proton, in addition to signals of aromatic moiety. Similarly, compounds 17b-g were prepared via reaction of ω -bromoacetophenone derivatives **16b-g** with ethyl 2-(2-carbamothioylhydrazono)propanoate (3) in boiling ethanol. Coupling of the latter compounds 17b-g with benzenediazonium chloride in ethanolic sodium acetate solution



15, 16 Ar: a, C₆H₅; b, 4-CH₃C₆H₄; c, 4-CH₃OC₆H₄; d, 4-NO₂C₆H₄ ; e, 4-ClC₆H₄; f, 4-BrC₆H₄; g, 4-CNC₆H₄

Scheme 5. Synthesis of ethyl 4-(aryl)-5-(2-phenylhydrazono)thiazol-2(5*H*)-ylidene)hydrazono)-propanoate **15a–g**.

gave ethyl 4-(aryl)-5-(2-phenylhydrazono)thiazol-2(5*H*)-ylidene)hydrazono)-propanoate **15b–g** (Scheme 5).

However, refluxing of compound **3** with *N*-phenyl-*C*-ethoxycarbonylmethano-hydra zonoyl chloride **12f** in ethanol in the presence of triethylamine yielded ethyl 2-((4-oxo-5-(2-phenylhydrazono)thiazolidin-2-ylidene)hydrazono)-propanoate (**18**) (Scheme 6). The structure of compound **18** based on elemental analysis and spectral data (see Experimental). Yield% of all new synthesized compounds **5–18** was mentioned in Table 1.

Antimicrobial screening

The antibacterial and antifungal activities of new synthesized compounds **5**, **13**, **15**, **17**, and **18** were studied by the disc diffusion method. The antibacterial activities were done on the following pathogenic organisms; the gram-positive bacteria *Staphylococcus aureus* and *Bacillus subtilis*, the gram negative bacteria *Escherichia coli* and *Pseudomonas aeruginosa*. Moreover, antifungal activities aganist *Aspergillus flavus* and *Candida albicans* were studied. The synthesized compounds were used at the concentration of 20 mg/mL using



Scheme 6. Synthesis of ethyl 2-(2-(4-oxo-5-(2-phenylhydrazono)-4,5-dihydrothiazol-2-yl)hydrazono) propanoate **18**.

Compounds	Yield %	Compounds	Yield %	Compounds	Yield %	
5a	65	13e	70	17a	77	
5b	72	13f	73	17b	70	
5c	69	15a	66	17c	66	
5d	73	15b	63	17d	74	
5e	63	15c	60	17e	73	
13a	67	15d	67	17f	77	
13b	66	15e	64	17g	73	
13c	68	15f	60	18	70	
13d	70	15g	68			

Table 1. Yield% of all new synthesized compounds 5–18.

DMSO as a solvent. The *Ampicillin* $10 \,\mu$ L/disc was used as a standard antibacterial agent and the *Amphotericin B* $20 \,\mu$ g/mL as standard antifungal agent. The results presented in Table 2 all compounds show no antibacterial and antifungal activities except compounds **15e**, **15f**, **17a**, **17b**, **17c**, and **18** however, the most potent compound exhibited antibacterial and antifungal activities was compound **17a**.

Compound **17a** showed high potentiality in growth inhibition of tested microorganisms with relative activity of standard antibiotics with relative activity of 42% in *B. subtilis*, 100% in *S. aureus*, 60% in *E. coli*, 50% in *P. aeruginosa*, and 66.7% in *C. albicans*. Regarding the structure-activity relationship the parent compound (Ar = Ph) **17a** showed high antimicrobial activity, while the presence of electron donating groups leads to decrease the antimicrobial activity.

In vitro susceptibility tests were performed to evaluate minimum inhibitory concentration (MIC) was measured by a broth dilution method [35–37]. MIC values were determined for the highly efficient antibacterial compounds using the most sensitive microorganisms. Compound **17a** achieved the lowest MIC value (high efficient derivative) against the sensitive bacterial strain *S. aureus* with MIC value 160 µg/ml, followed by

		Antimicrobial activity										
		Bacterial species (G ⁺)				Bacterial species (G ⁻)				Fungi		
		Bacillus subtilis		Staphylococcusaureus		Escherichia coli		Pseudomonasaeruginosa		Candida albicans		
Compounds		IZ	RA%	IZ	RA%	IZ	RA%	IZ	RA%	IZ	RA%	
Standard	Control: DMSO Ampicillin	0.0 26	0.0 100	0.0 21	0.0 100	0.0 25	0.0 100	0.0 26	0.0 100	0.0	0.0	
	Amphotericin B									21	100	
15e		0.0	0.0	11.0	52.4	0.0	0.0	0.0	0.0	0.0	0.0	
15f		9.0	34.6	15	71.4	9.0	36.0	9.0	34.6	0.0	0.0	
17a		11	42.0	21	100.0	15	60.0	13	50.0	14.0	66.7	
17b		0.0	0.0	11	52.4	0.0	0.0	0.0	0.0	0.0	0.0	
17c		00.0	0.0	11.0	52.4	11.0	44.0	10.0	38.5	14.0	66.7	
18		9.0	34.6	14.0	66.7	0.0	0.0	0.0	0.0	0.0	0.0	

Table 2. In vitro antibacterial and antifungal activities of compounds 15, 17 and 18 (Inhibition zone in mm).^a

 ${}^{a}G^{-} =$ Gram negative; $G^{+} =$ gram positive; R. A. = relative activity.

8 🔄 F. M. SALEH ET AL.

bacterial strain *E. coli* with MIC value $380 \,\mu$ g/ml and the highest MIC values against *C. albicans* MIC with value $420 \,\mu$ g/ml.

Experimental

Melting points were measured with a Stuart melting point apparatus and are uncorrected. The IR spectra were recorded using a FTIR Bruker–vector 22 spectrophotometer as KBr pellets. The ¹H and ¹³C NMR spectra were recorded in CDCl₃ or DMSO– d_6 as solvent on Varian Gemini NMR spectrometer at 300 and 75 MHz, respectively, using TMS as internal standard. Chemical shifts are reported as δ values in ppm. Mass spectra were recorded with a Shimadzu GCMS–QP–1000 EX mass spectrometer in EI (70 eV) model. The elemental analyses were performed at the Micro analytical center, Cairo University.

Synthesis of ethyl (aryl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)propanoate (5, 13)

Method A: A mixture of ethyl 2-(2-((methylthio)carbonothioyl)hydrazono)-propanoate (2) [25] (0.44 gm, 5 mmol) and the appropriate hydrazonoyl halides 4a-e and 12a-f (5 mmol) was dissolved in ethanol (50 mL). To the resulting solution triethylamine (2 mL) was added and reaction mixture was stirred for 6 h at room temperature. The resulting solid product that precipitated was collected, washed with ethanol and crystallized from a suitable solvent to afford the corresponding thiadiazole derivatives 5a-e and 13a-f. The products 5, 13 prepared together with their physical constants are listed below in yield (73%–63%).

Method B: To a solution of ethyl 2-(2-carbamothioylhydrazono)propanoate (3) [28] (0.95 gm, 5 mmol) and the appropriate hydrazonoyl chlorides 4a-f (5 mmol) was dissolved in ethanol (50 mL), triethylamine (2 mL) was added and reaction mixture was refluxed for 6 h. The resulting solid product that precipitated was collected, washed with ethanol and crystallized from a suitable solvent to afford the corresponding thiadiazole derivatives 5a-f in yield (60%–52%).

Ethyl 2-((3,5-*diphenyl*-1,3,4-*thiadiazol*-2(3H)-*ylidene*)*hydrazono*)*propanoate* (5a): Yellow crystals (EtOH), mp 143–144°C; IR (KBr) ν 1702 (C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.39 (t, J = 7 Hz, 3H, CH₃), 2.31 (s, 3H, CH₃), 4.33 (q, J = 7 Hz, 2H, CH₂) and 7.27–8.17 (m, 10H);¹³C NMR (75 MHz, CDCl₃) δ 14.2, 14.8, 61.3, 121.2, 122.8, 128.6, 128.9, 129.1, 130.6, 130.8, 137.9, 151.8, 152.2, 165.3, 167.4. MS (EI, 70 eV) m/z (%): 366 (M⁺, 14.8), 91 (100). Anal. Calcd. for C₁₉H₁₈N₄O₂S (366.4): C, 62.28; H, 4.95; N, 15.29; S, 8.75. Found: C, 62.16; H, 4.88; N, 15.24; S, 8.80.

Ethyl 2-((*3*-phenyl-5-((*E*)-styryl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)propanoate (**5b**): Yellow crystals (EtOH), mp 137–138°C; IR (KBr) ν 1699 (C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.40 (t, J = 7 Hz, 3H, CH₃), 2.30 (s, 3H, CH₃), 4.33 (q, J = 7 Hz, 2H, CH₂), 7.02 (d, J = 14 Hz, 1H, CH), 7.13 (d, J = 14 Hz, 1H, CH), 7.27–7.54 (m, 8H) and 8.10 (d, 2H);¹³C NMR (75 MHz, CDCl₃) δ 14.3, 14.7, 61.4, 118.5, 121.9, 126.4, 127.2, 128.7, 128.9, 129.5, 135.1, 137.6, 139.4, 151.9, 152.1, 165.1, 167.8. MS (EI, 70 eV) *m/z* (%): 392 (M⁺, 100). Anal. Calcd. for C₂₁H₂₀N₄O₂S (392.5): C, 64.27; H, 5.14; N, 14.28; S, 8.17. Found: C, 64.13; H, 5.20; N, 14.20; S, 8.23. *Ethyl 2-((5-(furan-2-yl)-3-(4-nitrophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)-propan-oate* (5c): Yellow crystals (DMF), mp 192–194°C; IR (KBr) ν 1689 (C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.39 (t, J = 7 Hz, 3H, CH₃), 2.34 (s, 3H, CH₃), 4.33 (q, J = 7 Hz, 2H, CH₂) and 6.60–8.47 (m, 7H);¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.6, 61.4, 108.2, 108.8, 110.2, 122.8, 135.9, 139.6, 140.6, 142.2, 150.7, 151.0, 153.9, 163.2. MS (EI, 70 eV) *m/z* (%): 401 (M⁺, 100). Anal. Calcd. for C₁₇H₁₅N₅O₅S (401.4): C, 50.87; H, 3.77; N, 17.45; S, 7.99. Found: C, 50.93; H, 3.70; N, 17.38; S, 7.85.

Ethyl 2-((3-(4-nitrophenyl)-5-(thien-2-yl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)-propanoate (5d): Yellow crystals (DMF), mp 186–188°C; IR (KBr) ν 1700 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.40 (t, J = 7 Hz, 3H, CH₃), 2.34 (s, 3H, CH₃), 4.34 (q, J = 7 Hz, 2H, CH₂) and 7.13–8.47 (m, 7H);¹³C NMR (75 MHz, CDCl₃) δ 14.0, 14.6, 61.5, 109.0, 109.2, 110.5, 123.9, 136.5, 139.3, 141.0, 142.8, 150.9, 151.5, 154.2, 163.5. Anal. Calcd. for C₁₇H₁₅N₅O₄S₂ (417.5): **C,** 48.91; H, 3.62; N, 16.78; S, 15.36. Found: C, 49.00; H, 3.69; N, 16.70; S, 15.39.

Ethyl 2-((3-phenyl-5-(phenylcarbamoyl)-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono) -propanoate (5e): Yellow crystals (EtOH), mp 145–146°C; IR (KBr) ν 3410 (NH), 1690, 1683 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.25 (t, J = 7 Hz, 3H, CH₃), 2.26 (s, 3H, CH₃), 4.30 (q, J = 7 Hz, 2H, CH₂), 7.20–8.00 (m, 10H) and 8.49 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 14.2, 14.4, 61.5, 120.6, 122.3, 122.5, 126.8, 127.0, 128.1, 134.7, 135.1, 140.8, 150.5, 151.2, 163.5, 164.2. MS (EI, 70 eV) m/z (%): 409 (M⁺, 21.3), 77 (100). Anal. Calcd. for C₂₀H₁₉N₅O₃S (409.5): C, 58.67; H, 4.68; N, 17.10; S, 7.83. Found: C, 58.55; H, 4.78; N, 17.04; S, 7.88.

Ethyl 2-((5-benzoyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)propanoate (13a): Yellow crystals (EtOH), mp 162–164°C; IR (KBr) ν 1712, 1697 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.39 (t, J = 7 Hz, 3H, CH₃), 2.28 (s, 3H, CH₃), 4.32 (q, J = 7 Hz, 2H, CH₂) and 7.27–8.35 (m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.7, 61.5, 122.4, 127.4, 128.5, 128.9, 130.5, 133.9, 134.3, 138.9, 152.8, 153.8, 164.9, 168.6, 182.3. MS (EI, 70 eV) *m/z* (%): 394 (M⁺, 11.7), 105 (100). Anal. Calcd. for C₂₀H₁₈N₄O₃S (394.4): C, 60.90; H, 4.60; N, 14.20; S, 8.13. Found: C, 60.99; H, 4.58; N, 14.28; S, 8.05.

Ethyl 2-((*5-*(*2-naphthoyl*)*-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)-propanoate* (13b): Yellow crystals (CH₃CN), mp 150–152°C; IR (KBr) ν 1720, 1709 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.40 (t, J = 7 Hz, 3H, CH₃), 2.30 (s, 3H, CH₃), 4.33 (q, J = 7 Hz, 2H, CH₂) and 7.27–9.02 (m, 12H);¹³C NMR (75 MHz, CDCl₃) δ 14.0, 14.4, 61.3, 120.2, 121.3, 122.9, 125.3, 126.7, 127.2, 127.5, 128.0, 128.9, 130.2, 131.2, 131.3, 133.5, 136.7, 140.5, 155.6, 157.2, 168.2, 183.9. Anal. Calcd. for C₂₄H₂₀N₄O₃S (444.5): C, 64.85; H, 4.54; N, 12.60; S, 7.21. Found: C, 64.93; H, 4.60; N, 12.78; S, 7.15.

Ethyl 2-((5-acetyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono)propanoate (13c): Yellow crystals (EtOH), mp 139–140°C; IR (KBr) ν 1712, 1690 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.37 (t, J = 7 Hz, 3H, CH₃), 2.26 (s, 3H, CH₃), 2.65 (s, 3H, CH₃CO), 4.30 (q, J = 7 Hz, 2H, CH₂) and 7.27–8.03 (m, 5H);¹³C NMR (75 MHz, CDCl₃) $\overline{\delta}$ 14.1, 14.7, 25.1, 61.5, 122.4, 127.4, 128.9, 138.8, 152.0, 153.7, 164.9, 169.2, 189.4. MS (EI, 70 eV) m/z (%): 332 (M⁺, 78.8), 259 (100). Anal. Calcd. for C₁₅H₁₆N₄O₃S (332.4): C, 54.20; H, 4.85; N, 16.86; S, 9.65. Found: C, 54.08; H, 4.78; N, 16.91; S, 9.70.

Ethyl 2-((3-phenyl-5-(thien-2-oyl)-1,3,4-thiadiazol-2(3H)-ylidene-hydrazono)-propanoate (13d): Yellow crystals (CH₃CN), mp 149–150°C; IR (KBr) ν 1710, 1699 (2C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.40 (t, J = 7 Hz, 3H, CH₃), 2.28 (s, 3H, CH₃), 4.37 (q, J = 7 Hz, 2H, CH₂) and 7.22–8.41 (m, 8H);¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.7, 61.5, 122.3, 127.3, 128.4, 128.9, 136.1, 136.4, 138.5, 139.0, 152.2, 153.8, 164.9, 168.5, 173.9. Anal. Calcd. for C₁₈H₁₆N₄O₃S₂ (400.5): C, 53.99; H, 4.03; N, 13.99; S, 16.01. Found: C, 53.87; H, 4.11; N, 13.87; S, 16.14.

Ethyl 2-((5-(furan-2-oyl)-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)hydrazono) propanoate (13e): Yellow crystals (CH₃CN), mp 190–192°C; IR (KBr) ν 1715, 1691 (2C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.38 (t, J = 7 Hz, 3H, CH₃), 2.27 (s, 3H, CH₃), 4.31 (q, J = 7 Hz, 2H, CH₂) and 6.65–8.05 (m, 8H);¹³C NMR (75 MHz, CDCl₃) δ 14.0, 14.6, 61.5, 121.0, 127.1, 128.8, 128.9, 135.9, 136.3, 138.1, 139.0, 152.0, 153.9, 164.4, 168.2, 173.9. MS (EI, 70 eV) m/z (%): 384 (M⁺, 55.4), 95 (100). Anal. Calcd. for C₁₈H₁₆N₄O₄S (384.4): C, 56.24; H, 4.20; N, 14.58; S, 8.34. Found: C, 56.18; H, 4.09; N, 14.64; S, 8.43.

Ethyl 5-((1-ethoxy-1-oxopropan-2-ylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4thiadiazole-2-carboxylate (13f): Yellow crystals (EtOH), mp 109–110°C; IR (KBr) ν 1702, 1692 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.37 (t, J = 7 Hz, 6H, 2CH₃), 2.25 (s, 3H, CH₃), 4.30 (q, J = 7 Hz, 2H, CH₂), 4.43 (q, J = 7 Hz, 2H, CH₂) and 7.27–8.02 (m, 5H);¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.6, 53.5, 61.5, 63.0, 122.5, 127.4, 128.8, 138.8, 144.1, 153.4, 158.2, 164.8, 168.9. MS (EI, 70 eV) m/z (%): 362 (M⁺, 100). Anal. Calcd. for C₁₆H₁₈N₄O₄S (362.4): C, 53.03; H, 5.01; N, 15.46; S, 8.85. Found: C, 53.11; H, 4.85; N, 15.33; S, 8.88.

Synthesis of ethyl 2-(2-(4-(aryl)thiazol-2-yl)hydrazono)propanoate (17)

To a solution ethyl 2-(2-carbamothioyl-hydrazono)propanoate 3 (0.95 gm, 5 mmol) in ethanol (50 mL), the appropriate phenacyl bromides 16a-g (5.0 mmol) was added and reaction mixture was refluxed for 6 h. The resulting solid product that precipitated was collected and crystallized from a suitable solvent to afford the corresponding thiazole derivatives 17a-g.

Ethyl 2-(2-(4-phenylthiazol-2-yl)hydrazono)propanoate (17a): Yellow crystals (CH₃ CN), mp 131–133°C; IR (KBr) ν 1700 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.34 (t, J = 7 Hz, 3H, CH₃), 2.18 (s, 3H, CH₃), 4.22 (q, J = 7 Hz, 2H, CH₂), 7.04–7.38 (m, 6H) and 9.22 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 11.5, 14.1, 61.5, 118.2, 120.1, 122.3, 129.3, 131.2, 147.7, 150.1, 151.3, 165.7; MS (EI, 70 eV) m/z (%): 289 (M⁺, 26), 216 (100). Anal. Calcd. for C₁₄H₁₅N₃O₂S (289.4): C, 58.11; H, 5.23; N, 14.52; S, 11.08. Found: C, 58.02; H, 5.31; N, 14.59; S, 10.97.

Ethyl 2-(2-(4-(*p*-tolyl)*thiazol*-2-*yl*)*hydrazono*)*propanoate* (17b): Yellow crystals (EtOH), mp 149–150°C; IR (KBr) ν 1706 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.37 (t, J = 7 Hz, 3H, CH₃), 1.96 (s, 3H, CH₃), 2.36 (s, 3H, 4-CH₃C₆H₄), 4.30 (q, J = 7 Hz, 2H, CH₂), 6.91 (s, 1H, CH), 7.18 (d, J = 8.5 Hz, 2H, Ar), 7.64 (d, J = 8.5 Hz, 2H, Ar) and 8.89 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 11.7, 14.1, 21.1, 61.5, 104.2, 125.7, 129.4, 131.4, 137.9, 138.3, 151.2, 164.2, 168.6. MS (EI, 70 eV) *m/z* (%): 303 (M⁺, 38), 230 (100). Anal. Calcd. for C₁₅H₁₇N₃O₂S (303.4): C, 59.39; H, 5.65; N, 13.85; S, 10.57. Found: C, 59.22; H, 5.73; N, 13.79; S, 10.63.

Ethyl 2-(2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazono)propanoate (17c): Yellow crystals (MeOH), mp 107–108°C; IR (KBr) ν 1697 (C = O) cm⁻¹; ¹H NMR (300 MHz,

CDCl₃) δ 1.34 (t, J = 7 Hz, 3H, CH₃), 2.03 (s, 3H, CH₃), 3.80 (s, 3H, 4-CH₃OC₆H₄), 4.27 (q, J = 7 Hz, 2H, CH₂), 6.80 (s, 1H, CH), 6.90 (d, J = 8.5 Hz, 2H, Ar), 7.66 (d, J = 8.5 Hz, 2H, Ar) and 8.97 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 12.0, 14.0, 55.2, 61.6, 102.8, 114.1, 126.1, 127.1, 139.4, 149.7, 159.6, 163.9, 168.7. MS (EI, 70 eV) m/z (%): 319 (M⁺, 45), 246 (100). Anal. Calcd. for C₁₅H₁₇N₃O₃S (319.4): C, 56.41; H, 5.37; N, 13.16; S, 10.04. Found: C, 56.29; H, 5.41; N, 13.20; S, 9.97.

Ethyl 2-(2-(4-(4-nitrophenyl)thiazol-2-yl)hydrazono)propanoate (17d): Yellow crystals (CH₃CN), mp 198–200°C; IR (KBr) ν 1690 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J = 7 Hz, 3H, CH₃), 2.14 (s, 3H, CH₃), 4.24 (q, J = 7 Hz, 2H, CH₂) 7.02 (s, 1H, CH), 7.45 (d, J = 9 Hz, 2H, Ar), 7.87 (d, J = 9 Hz, 2H, Ar) and 9.28 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 11.7, 14.0, 61.6, 119.8, 123.7, 127.8, 130.9, 133.1, 138.5, 150.6, 164.2, 168.4. MS (EI, 70 eV) m/z (%): 334 (M⁺, 17), 261 (100). Anal. Calcd. for C₁₄H₁₄N₄O₄S (334.3): C, 50.29; H, 4.22; N, 16.76; S, 9.59. Found: C, 50.17; H, 4.30; N, 16.68; S, 9.66.

Ethyl 2-(2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazono)propanoate (17e): Yellow crystals (EtOH), mp 167–168°C; IR (KBr) ν 1701 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.33 (t, J = 7 Hz, 3H, CH₃), 1.91 (s, 3H, CH₃), 4.27 (q, J = 7 Hz, 2H, CH₂), 6.94 (s, 1H, CH), 7.31 (d, J = 8 Hz, 2H, Ar), 7.65 (d, J = 8 Hz, 2H, Ar) and 9.20 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 11.6, 14.1, 61.6, 105.5, 127.0, 128.8, 132.7, 133.7, 138.3, 150.0, 164.1, 168.5. MS (EI, 70 eV) m/z (%):326 (M + 2, 2), 325 (M + 1, 10) 324 (M⁺, 6), 250 (100). Anal. Calcd. for C₁₄H₁₄ClN₃O₂S (323.8): C, 51.93; H, 4.36; Cl, 10.95; N, 12.98; S, 9.90. Found: C, 51.80; H, 4.41; Cl, 10.88; N, 12.91; S, 9.98.

Ethyl 2-(2-(4-(4-bromophenyl)thiazol-2-yl)hydrazono)propanoate (17f): Yellow crystals (CH₃CN), mp 169–170°C; IR (KBr) ν 1689 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, *J* = 7 Hz, 3H, CH₃), 2.14 (s, 3H, CH₃), 4.22 (q, *J* = 7 Hz, 2H, CH₂), 6.91 (s, 1H, CH), 7.27 (d, *J* = 8.5 Hz, 2H, Ar), 7.55 (d, *J* = 8.5 Hz, 2H, Ar) and 9.18 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 11.5, 14.2, 61.3, 115.2, 126.1, 127.9, 133.1, 134.7, 138.5, 150.1, 164.2, 168.6. MS (EI, 70 eV) *m/z* (%): 370 (M + 2, 4), 369 (M + 1, 22), 368 (M⁺, 5), 296 (100). Anal. Calcd. for C₁₄H₁₄BrN₃O₂S (368.2): C, 45.66; H, 3.83; Br, 21.70; N, 11.41; S, 8.71. Found: C, 45.57; H, 3.90; Br, 21.79; N, 11.33; S, 8.65.

Ethyl 2-(2-(4-(4-cyanophenyl)thiazol-2-yl)hydrazono)propanoate (17 g): Yellow crystals (CH₃CN), mp 171–172°C; IR (KBr) ν 2218 (CN), 1700 (C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.35 (t, J = 7 Hz, 3H, CH₃), 2.10 (s, 3H, CH₃), 4.29 (q, J = 7 Hz, 2H, CH₂), 7.12 (s, 1H, CH), 7.64 (d, J = 8.5 Hz, 2H, Ar) 7.85 (d, J = 8.5 Hz, 2H, Ar) and 9.16 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 11.5, 14.1, 61.8, 108.3, 111.1, 118.8, 126.2, 132.5, 132.5, 138.3, 138.4, 149.5, 163.9, 168.0. MS (EI, 70 eV) m/z (%): 314 (M⁺, 20), 241 (100). Anal. Calcd. for C₁₅H₁₄N₄O₂S (314.4): C, 57.31; H, 4.49; N, 17.82; S, 10.20. Found: C, 57.19; H, 4.57; N, 17.90; S, 10.07.

Synthesis of ethyl 4-(aryl)-5-(2-phenylhydrazono)thiazol-2(5H)-ylidene)hydrazono)-propanoate 15a–g

Method A: To the appropriate solution of thiazoles 17a-g (5.0 mmol) in ethanol (100 mL), sodium acetate (0.41 g, 5.0 mmol) was added. To the resulting cold mixture, the prepared as usual by diazotizing aniline (0.5 mL, 5.0 mmol) in hydrochloric acid (6, 3 mL) with sodium nitrite (0.35 g, 5.0 mmol) in water (5 mL), was added portion wise over 30 min.

12 🕞 F. M. SALEH ET AL.

The reaction mixture was stirred for further 1 h while cooling in an ice-bath. The solid that precipitated was filtered, washed with water, dried and finally crystallized from suitable solvent to give **15a–g**.

Ethyl 2-(2-(4-phenyl-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15a): Red crystals (CH₃CN), mp 178–180°C; IR (KBr) ν 3429 (NH), 1697 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J = 7 Hz, 3H, CH₃), 2.14 (s, 3H, CH₃), 4.27 (q, J = 7 Hz, 2H, CH₂), 7.22–8.98 (m, 10H) and 11.38 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.5, 55.0, 109.3, 118.2, 125.8, 128.2, 128.5, 129.6, 130.1, 132.5, 140.8, 148.3, 150.8, 163.8, 164.9. MS (EI, 70 eV) m/z (%): 393 (M⁺, 65), 77 (100). Anal. Calcd. for C₂₀H₁₉N₅O₂S (393.5): C, 61.05; H, 4.87; N, 17.80; S, 8.15. Found: C, 60.89; H, 4.77; N, 17.91; S, 8.07.

Ethyl 2-(2-(5-(phenyldiazenyl)-4-(p-tolyl)thiazol-2-yl)hydrazono)propanoate (15b): Red crystals (EtOH), mp 129–130°C; IR (KBr) ν 3423 (NH), 1700 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.36 (t, J = 7 Hz, 3H, CH₃), 2.21 (s, 3H, CH₃), 2.42 (s, 3H, 4-CH₃C₆H₄), 3.90 (s, 1H, NH), 4.34 (q, J = 7 Hz, 2H, CH₂) and 7.07–8.37 (m, 9H);¹³C NMR (75 MHz, CDCl₃) δ 13.9, 14.1, 19.7, 21.4, 21.5, 61.8, 61.9, 122.6, 128.9, 129.0. 129.2, 129.6, 130.1, 131.2, 139.5, 162.7, 168.2. MS (EI, 70 eV) *m/z* (%): 407 (M⁺, 96), 77 (100). Anal. Calcd. for C₂₁H₂₁N₅O₂S (407.5): C, 61.90; H, 5.19; N, 17.19; S, 7.87. Found: C, 61.79; H, 5.04; N, 17.24; S, 7.80.

Ethyl 2-(2-(4-(4-methoxyphenyl)-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15c): Red crystals (EtOH), mp 77–78°C; IR (KBr) ν 3427 (NH), 1695 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J = 7 Hz, 3H, CH₃), 2.14 (s, 3H, CH₃), 3.22 (s, 3H, 4-CH₃OC₆H₄), 4.28 (q, J = 7 Hz, 2H, CH₂), 7.19–8.66 (m, 9H) and 11.77 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.3, 55.1, 55.9, 109.8, 117.6, 125.3, 128.8, 129.0, 129.7, 130.9, 132.4, 141.3, 148.8, 150.1, 163.0, 164.5. MS (EI, 70 eV) *m/z* (%): 423 (M⁺, 100). Anal. Calcd. for C₂₁H₂₁N₅O₃S (423.5): C, 59.56; H, 5.00; N, 16.54; S, 7.57. Found: C, 59.44; H, 5.12; N, 16.48; S, 7.49.

Ethyl 2-(2-(4-(4-nitrophenyl)-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15d): Red crystals (CH₃CN), mp 236–238°C; IR (KBr) ν 3422 (NH), 1690 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J = 7 Hz, 3H, CH₃), 2.14 (s, 3H, CH₃), 4.30 (q, J = 7 Hz, 2H, CH₂), 7.09–8.56 (m, 9H) and 11.78 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 13.9, 14.1, 55.7, 122.4, 124.6, 127.8, 127.9, 128.0, 128.5, 134.2, 138.9, 143.5, 145.9, 150.1, 163.4, 166.8. MS (EI, 70 eV) m/z (%): 438 (M⁺, 48), 77 (100). Anal. Calcd. for C₂₀H₁₈N₆O₄S (438.5): C, 54.79; H, 4.14; N, 19.17; S, 7.31. Found: C, 54.66; H, 4.02; N, 19.25; S, 7.40.

Ethyl 2-(2-(4-(4-chlorophenyl)-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15e): Red crystals (EtOH), mp 123–124°C; IR (KBr) ν 3429 (NH), 1699 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J = 7 Hz, 3H, CH₃), 2.15 (s, 3H, CH₃), 4.29 (q, J = 7 Hz, 2H, CH₂), 7.23–8.57 (m, 9H) and 11.67 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 14.0, 14.1, 55.8, 124.7, 125.0, 125.2, 127.8, 128.0, 128.6, 130.2, 132.5, 135.1, 143.4, 150.2, 163.2, 166.3. MS (EI, 70 eV) m/z (%): 430 (M + 2, 4), 429 (M + 1), 428 (M⁺, 18), 77 (100). Anal. Calcd. for C₂₀H₁₈ClN₅O₂S (427.9): C, 56.14; H, 4.24; Cl, 8.28; N, 16.37; S, 7.49. Found: C, 56.02; H, 4.17; Cl, 8.17; N, 16.45; S, 7.38.

Ethyl 2-(2-(4-(4-bromophenyl)-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15f): Red crystals (EtOH), mp 129–130°C; IR (KBr) ν 3424 (NH), 1690 (C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.32 (t, *J* = 7 Hz, 3H, CH₃), 2.17 (s, 3H, CH₃), 4.20 (q, J = 7 Hz, 2H, CH₂), 7.39–8.49 (m, 9H) and 11.70 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 14.0, 14.2, 55.7, 123.1, 124.7, 125.1, 126.9, 127.4, 128.1, 130.5, 132.8, 135.7, 142.9, 150.5, 163.1, 166.7. MS (EI, 70 eV) m/z (%): 474 (M + 2, 7), 473 (M + 1, 28), 472 (M⁺, 23), 77 (100). Anal. Calcd. for C₂₀H₁₈BrN₅O₂S (472.4): C, 50.86; H, 3.84; Br, 16.92; N, 14.83; S, 6.79. Found: C, 50.77; H, 3.78; Br, 16.85; N, 14.79; S, 6.68.

Ethyl 2-(2-(4-(4-cyanophenyl)-5-(phenyldiazenyl)thiazol-2-yl)hydrazono)propanoate (15 g): Red crystals (CH₃CN), mp 198–200°C; IR (KBr) ν 3423 (NH), 2215 (CN), 1697 (C = O) cm⁻¹;¹H NMR (300 MHz, CDCl₃) δ 1.25 (t, J = 7 Hz, 3H, CH₃), 2.12 (s, 3H, CH₃), 4.18 (q, J = 7 Hz, 2H, CH₂), 7.52–8.40 (m, 9H) and 11.76 (s, 1H, NH); ¹³C NMR (75 MHz, CDCl₃) δ 13.9, 14.0, 55.6, 112.2, 118.3, 120.7, 124.1, 126.4, 127.4, 128.7, 130.1, 132.3, 135.8, 142.3, 150.4, 163.5, 166.5. MS (EI, 70 eV) m/z (%): 418 (M⁺, 76), 77 (100). Anal. Calcd. for C₂₁H₁₈N₆O₂S (418.5): C, 60.27; H, 4.34; N, 20.08; S, 7.66. Found: C, 60.12; H, 4.25; N, 20.17; S, 7.58.

Alternative method for synthesis of Ethyl 2-(2-(4-phenyl-5-(phenyldiazenyl) thiazol-2-yl)hydrazono)propanoate (15a)

A mixture of 2-oxo-*N*,2-diphenylacetohydrazonoyl bromide **12a** (0.3 g, 1 mmol), compound **3** (0.13 g, 1 mmol) and triethylamine in ethanol (20 mL) was refluxed for 3 h. The solid was collected and crystallized from ethanol afforded identical product mp, mixed mp and spectra with compound **15a**.

Synthesis of ethyl 2-((4-oxo-5-(2-phenylhydrazono)thiazolidin-2- ylidene) hydrazono)-propanoate (18)

To a solution ethyl 2-(2-carbamothioylhydrazono)propanoate **3** (0.95 gm, 5 mmol) and *N*-phenyl-*C*-ethoxycarbonylmethanohydrazonoyl chloride **12f** (1.13 gm, 5 mmol) was dissolved in ethanol (50 mL), triethylamine (2 mL) was added and reaction mixture was refluxed for 6 h. The resulting solid product that precipitated was collected and crystallized from ethanol to afford ethyl 2-((4-oxo-5-(2-phenylhydrazono)thiazolidin-2-ylidene)hydrazono)propanoate (**14**): Yellow crystals, mp 176–178°C; IR (KBr) ν 3422 (NH), 1697, 1686 (2C = O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.29 (t, *J* = 7 Hz, 3H, CH₃), 2.17 (s, 3H, CH₃), 4.20 (q, *J* = 7 Hz, 2H, CH₂), 7.01–7.37 (m, 5H), 11.55 (s, 1H, NH) and 11.70 (s, 1H, NH);¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.2, 56.4, 112.9, 121.2, 128.5, 136.9, 142.3, 146.8, 156.3, 163.5, 166.0. MS (EI, 70 eV) *m/z* (%): 333 (M⁺, 10), 307 (100). Anal. Calcd. for C₁₄H₁₅N₅O₃S (333.4): C, 50.44; H, 4.54; N, 21.01; S, 9.62. Found: C, 50.32; H, 4.67; N, 20.93; S, 9.49.

Antimicrobial assay

Antimicrobial activity of the tested compounds was determined using a modified Kirby-Bauer disc diffusion method [38]. Briefly, $100 \,\mu$ l of the test bacteria/fungi were grown in 10 ml of fresh media until they reached a count of approximately 10^8 cells/ml for bacteria or 10^5 cells/ml for fungi [39]. $100 \,\mu$ l of microbial suspension was spread onto agar plates corresponding to the broth in which they were maintained. Of the many media available, NCCLS recommends Mueller-Hinton agar due to: it results in good batch-to-batch reproducibility. Disc diffusion method for filamentous fungi tested by using approved standard method (M38-A) developed by the (NCCLS, 2002) [40] for evaluating the susceptibilities of filamentous fungi to antifungal agents. Disc diffusion method for yeasts developed by using approved standard method (M44-P) by the (NCCLS, 2003) [41].

Minimum inhibitory concentration study

The MIC values were measured by the broth dilution method [37,42]. Five hundred micro liters of a stock solution (10.24 mg/mL) of each tested compound in dimethyl sulfox-ide (DMSO) were prepared and then diluted with Mueller-Hinton broth to 1024 µg/mL. The strains were grown briefly at 37°C in Mueller-Hinton media. After 5 h of bacterial growth, the bacterial culture was diluted to obtain a concentration of 5×10^5 cells/mL. Then, 150 µL bacterial suspensions were added to each well of the flat-bottomed 96-well tissue culture plate. Two-fold serial dilutions were carried out from the fist well to the tenth well; the final concentrations of the compounds ranged from 1 to 512 µg/mL; and excess media (150 µL) were discarded from the last well. The plates were incubated at 37°C for 24 h in an electro-heating standing temperature cultivator and were read visually. The MIC of the sample showing no turbidity was recorded as the lowest concentration of compound that inhibited bacterial growth completely. Each assay was run in triplicate.

Conclusion

In summary, ethyl pyruvate proved to be useful precursor for convenient synthesis of new thiadiazoles and thiazoles having many functional groups that have not been reported hitherto. As antimicrobial results showed that ethyl 2-(2-(4-phenylthiazol-2-yl)hydrazono)propanoate (**17a**) achieved the lowest MIC value (high efficient derivative) against the sensitive bacterial strain *S. aureus* with MIC value 160 µg/ml.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Fatma M. Saleh http://orcid.org/0000-0003-0451-4802 *Abdou O. Abdelhamid* http://orcid.org/0000-0002-5380-7727 *Hamdi M. Hassaneen* http://orcid.org/0000-0003-0963-4192

References

- Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med. 2007;261(4):349–362. doi:10.1111/j.1365-2796.2007.01789.x.
- [2] Kao KK, Fink MP. The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol. 2010;80(2):151–159.
- [3] Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol. 2008;21:160–167.
- [4] Kung C-W, Lee Y-M, Cheng P-Y, et al. Ethyl pyruvate reduces acute lung injury via regulation of iNOS and HO-1 expression in endotoxemic rats. J Surg Res. 2011;167(2):e323–e331.

- [5] Shang G-H, Lin D-J, Xiao W, et al. Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model. Respir Res. 2009;10(1):91. doi:10.1186/1465-9921-10-91.
- [6] Zhu Q, Wang H, Wang H, et al. Protective effects of ethyl pyruvate on lipopolysaccharide-induced acute lung injury through inhibition of autophagy in neutrophils. Mol Med Rep. 2017;15(3):1272–1278. doi:10.3892/mmr.2017.6118.
- Baunacke M, Horn LC, Trettner S, et al. Exploring glyoxalase 1 expression in prostate cancer tissues: targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties. Prostate. 2014;74(1):48–60. doi:10.1002/pros.22728.
- [8] Muller AJ, DuHadaway JB, Jaller D, et al. Immunotherapeutic suppression of indoleamine 2, 3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res. 2010;70(5):1845– 1853.
- [9] Worku N, Stich A, Daugschies A, et al. Ethyl pyruvate emerges as a safe and fast acting agent against trypanosoma brucei by targeting pyruvate kinase activity. PLoS One. 2015;10(9):e0137353. doi:10.1371/journal.pone.0137353.
- [10] Montgomery CM, Webb JL. Metabolic studies on heart mitochondria II. The inhibitory action of parapyruvate on the tricarboxylic acid cycle. J Biol Chem. 1956;221(1):359–368.
- [11] Cruz Jr. RJ, Harada T, Sasatomi E, et al. Effects of ethyl pyruvate and other α -keto carboxylic acid derivatives in a rat model of multivisceral ischemia and reperfusion. J Surg Res. 2011;165(1):151–157.
- [12] Tauxe GM, MacWilliam D, Boyle SM, et al. Targeting a dual detector of skin and CO2 to modify mosquito host seeking. Cell. 2013;155(6):1365–1379.
- [13] Turner SL, Ray A. Modification of CO 2 avoidance behaviour in drosophila by inhibitory odorants. Nat. 2009;461(7261):277–281.
- [14] Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8(9):881–890.
- [15] Geffken D, Rayner DR. Fungicidal oxazolidinones. US Pat. 1994;5:356–908.
- [16] Adams Jr. JB, Geffken D, Rayner DR. Fungicidal oxazolidinones. US Pat. 1993;5:223-523.
- [17] Shawali AS, Abdelhamid AO. New routes to aroylthiadiazolines and arylazothiazoles from phenylglyoxalyl bromide arylhydrazones and phenacyl thiocyanate. J Heterocycl Chem. 1976;13(1):45–49. doi:10.1002/jhet.5570130108.
- [18] Shawali SA, Hassaneen HM. Chemistry of aliphatic hydrazonyl bromides. Part I-reactions of N-(4-nitrophenyl) acetohy-drazonyl bromide with nucleophiles and 1, 3-dipolarophiles. Indian J Chem. 1976;14(B):425–427.
- [19] Pocar D, Rossi LM, Stradi R. Preparation of 1-aryl-4,5- and 5,5-diamino-4,5-dihydropyrazoles and 4- and 5-amino-1-arylpyrazoles. Synthesis (Mass). 1976;1976(10):684–685. doi:10.1055/ s-1976-24158.
- [20] Hassaneen HM, Mousa HAH. C-(2-thinyl)-n-arylformohydrazidoyl chlorides in the synthesis of selenadiazolines and thiadiazolines. Sulfur Lett. 1988;7(31):93–102.
- [21] Hassaneen HM, Shawali AS, Abdallah TA. One-step synthesis of 2, 3-dihydrothiadiazole derivatives from hydrazonoyl halides. Sulfur Lett. 1992;15(3):103–109.
- [22] Hassaneen HM, Shawali AS, Elwan NM, et al. Reaction of 1-(2-naphthoyl) methyl-2-dimethyl sulfonium bromide with N-nitroso-N-arylacetamides and reactions of the products with some nucleophiles. Sulfur Lett. 1992;13(6):273–285.
- [23] Eweiss NF, Osman A. Synthesis of heterocycles. Part II. New routes to acetylthiadiazolines and alkylazothiazoles. J Heterocycl Chem. 1980;17(8):1713–1717. doi:10.1002/jhet.5570170814.
- [24] Farag AM, Hassaneen HM, Abbas IM, et al. Synthesis and reactions of some 2-thienyl- and 2-thenoyl-derivatives of thiazole and thiadiazoline and their selenium analogs. Phosphorous Sulfur Relat Elem. 1988;40(3–4):243–249. doi:10.1080/03086648808072921.
- [25] Pedersen L-EK, Svendsen A, Klemmensen PD. Synthesis and insect growth regulating activity of thiosemicarbazones of methyl 2-pyridyl ketones. Pestic Sci. 1984;15(5):462–470. doi:10.1002/ps.2780150507.
- [26] Toyooka K, Toyooka K, Takeuchi Y, et al. Synthesis of 2,5-disubstituted 3-(4-chlorobenzoyl)-2,3-dihydro-2-methyl-1,3,4-thiadiazole derivatives. Heterocycles. 1991;32(9):1813. doi:10. 3987/COM-91-5813.

16 😉 F. M. SALEH ET AL.

- [27] Ferrari MB, Fava GG, Pelizzi C, et al. Thiosemicarbazones as co-ordinating agents. Part 5. Zinc complexes derived from methyl pyruvate- and pyridoxal-thiosemicarbazone. J Chem Soc Dalt Trans. 1992;14:2153. doi:10.1039/dt9920002153.
- [28] Corrêa CC, Graúdo JEJC, de Oliveira LFC, et al. Ethyl 2-[(carbamothioylamino) imino] propanoate. Crystallogr Sect E Struct Reports Online. 2011;67(8):01967–01968.
- [29] Abdelhamid AO, Gomha SM, Kandeel SM. Synthesis of certain new thiazole and 1,3,4thiadiazole derivatives via the utility of 3-acetylindole. J Heterocycl Chem. 2017;54(2):1529– 1536. doi:10.1002/jhet.2740.
- [30] Abdelhamid AO, Sayed AR. Reaction of hydrazonoyl halides 52: synthesis and antimicrobial activity of some new pyrazolines and 1, 3, 4-thiadiazolines. Phosphorus Sulfur Silicon Relat Elem. 2007;182(8):1767–1777. doi:10.1080/10426500701313938.
- [31] Abdelhamid AO, Zohdi HF, Rateb NM. Reactions with hydrazonoyl halides. Part 21. Reinvestigation of the reactions of hydrazonoyl bromides with 1, 1-dicyanothioacetanilide. J Chem Res. 1999;23(3):184–185.
- [32] Zohdi HF, Rateb NM, Sallam MM, et al. Reactions with hydrazonoyl halides. Part 20. 1 synthesis of new unsymmetrical azines, dihydro-1, 3, 4-thiadiazoles and 5-arylazothiazoles. J Chem Res Synopses. 1998;12:742–743.
- [33] Abdelhamid AO, Abdelgawad SM, El-Sharnoby SF. Reactions of hydrazonoyl halides 33 1: synthesis of some new 2,3-dihydro-1,3,4-thiadiazoles containing pyrazol-3-yl, indolin-2-one-2-yl and indan-1,3-dione-2-yl moieties. Phosphorus Sulfur Silicon Relat Elem. 2002;177(11):2699–2709. doi:10.1080/10426500214563.
- [34] Abdelhamid AO, Abdel-Wahab BAM, Al-Atoom AA. Reactions of hydrazonoyl halides 371: synthesis of triazolo[4,3-a]pyrimidines, 1,3,4-thiadiazoles and 1,3,4-selenadiazoles. Phosphorus Sulfur Silicon Relat Elem. 2004;179(3):601–613. doi:10.1080/10426500490422272.
- [35] Geng Z-Z, Zhang J-J, Lin J, et al. Novel cajaninstilbene acid derivatives as antibacterial agents. Eur J Med Chem. 2015;100:235–245.
- [36] Lei X, Li J, Liu B, et al. Separation and identification of four new compounds with antibacterial activity from portulaca oleracea L. Molecules. 2015;20(9):16375–16387.
- [37] Jordão AK, Novais J, Leal B, et al. Synthesis using microwave irradiation and antibacterial evaluation of new N, O-acetals and N, S-acetals derived from 2-amino-1, 4-naphthoquinones. Eur J Med Chem. 2013;63:196–201.
- [38] Bauer AW, Kirby WM, Sherris JC, et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493–496.
- [39] Pfaller MA, Burmeister L, Bartlett MS, et al. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol. 1988;26(8):1437–1441.
- [40] Nccls. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard — second edition serving the world 'S medical science community through voluntary consensus; 2002; Vol. 22.
- [41] Rex JH, Johnson EM, Ghannoum MA, et al. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A; 2009; Vol. 24.
- [42] Suresh N, Nagesh HN, Renuka J, et al. Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1,4dihydro-4-oxo-7-(4-(2-(4-substitutedpiperazin-1-yl)acetyl)piperazin-1-yl)quinoline-3-carbo xylic acid derivatives as anti-tubercular and antibacterial agents. Eur J Med Chem. 2014;71:324–332. doi:10.1016/J.EJMECH.2013.10.055.